Open an Account
search icon
2
NOTIFICATIONS
Best Algo trading app in India
Bigul

Glenmark Pharmaceuticals Ltd reply to clarification sought by the exchange

 The Exchange had sought clarification from Glenmark Pharmaceuticals Ltd with respect to news article appearing on ET Now on March 20, 2015 titled "Delhi High court restrains Glenmark Pharma from manufacturing and marketing Zeta, Zeta-met used to treat Diabetes"Glenmark Pharmaceuticals Ltd replied stating "We state as under:Division bench of Delhi high court has injuncted today Glenmark from manufacturing Zita and Zita- met....
23-03-2015
Bigul

Updates on Scheme of Amalgamation

 Glenmark Pharmaceuticals Ltd has informed BSE that the Hon'ble Bombay High Court has on March 20, 2015 orally pronounced an Order, approving the scheme of amalgamation of Glenmark Generics Limited and Glenmark Access Limited with Glenmark Pharmaceuticals Limited under Sections 391 to 394 of the Companies Act, 1956.Further the certified true copy of the said Order is being awaited and the scheme of amalgamation will only be effective after...
20-03-2015
Bigul

Clarification sought from Glenmark Pharmaceuticals Ltd

 The Exchange has sought clarification from Glenmark Pharmaceuticals Ltd with respect to news article appearing on ET NOW on March 20, 2015 titled "Delhi High court restrains Glenmark Pharma from manufacturing and marketing Zeta, Zeta-met used to treat Diabetes." The reply is awaited.
20-03-2015
Bigul

Glenmark receives approval for generic Seretide in Russia

 Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated March 12, 2015, titled "Glenmark receives approval for generic Seretide in Russia".
12-03-2015
Bigul

Glenmark announces approval and launch of Trandolapril & Verapamil Hydrochloride (HCI) Extended Release Tablets in the US

 Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated February 26, 2015, titled "Glenmark announces approval and launch of Trandolapril & Verapamil Hydrochloride (HCI) Extended Release Tablets in the US"
26-02-2015
Bigul

Glenmark announces approval and launch of Ashlyna TM Extended - Cycle Oral Contraceptive Tablets in the US

 Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated February 25, 2015, titled "Glenmark announces approval and launch of Ashlyna TM Extended - Cycle Oral Contraceptive Tablets in the US".
25-02-2015
Bigul

Outcome of Board Meeting

 Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 12, 2015 allotted 10,200 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
12-02-2015
Bigul

Announces Q3 results, Results Press Release, Management Discussion & Analysis & Limited Review Report for the Quarter ended December 31, 2014

 Glenmark Pharmaceuticals Ltd has announced the following results for the quarter ended December 31, 2014:The Unaudited Standalone results for the Quarter ended December 31, 2014The Company has posted a net profit of Rs. 1167.30 million for the quarter ended December 31, 2014 where as the same was at Rs. 584.09 million for the quarter ended December 31, 2013. Total Income is Rs. 6692.97 million for the quarter ended December 31, 2014...
12-02-2015
Bigul

Q3 results on Feb 12, 2015

 Glenmark Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 12, 2015 to consider and approve the Company's Unaudited Financial Statements for the Third Quarter ended December 31, 2014 (Q3).Further, as per the "Code of Conduct for Prevention of Insider Trading" of the Company, the trading window shall remain closed for Directors and other designated employees of the Company...
30-01-2015
Bigul

Investor Presentation

 Glenmark Pharmaceuticals Ltd has submitted to BSE a copy of "Investor Presentation of the Company at J P Morgan Healthcare Conference in San Francisco, USA"
14-01-2015
Next Page
Close

Let's Open Free Demat Account